• 1. The Seond Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou 310053, China;
  • 2. Department of Ophthalmology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou 310014, China;
Wu Miaoqin, Email: eyewmq@126.com
Export PDF Favorites Scan Get Citation

Diabetic retinopathy (DR) is one of the most frequent complications of diabetes (T2DM), which is the main eye disease causing blindness in adults in recent years. At present, glucagon-like peptide-1 receptor agonists (GLP-1RA) have become the main drugs used in the treatment of diabetes due to its superior hypoglycemic, lipid-lowering, hypertensive and cardiovascular effects. A large number of studies have shown that GLP-1RA drugs can protect retinal microvascular and optic nerves in the treatment of diabetes through various ways, but some studies have found that GLP-1RA drugs represented by semaglutide may lead to the progress of DR. Therefore, GLP-1RA should be used cautiously for patients who with severe non-proliferative DR or proliferative DR. Regardless of whether T2DM patients are complicated with DR, the fundus retinal condition should be monitored regularly after the use of GLP-1RA drugs, and timely countermeasures should be taken when DR occurs and develops. The benefits of GLP-1RA used by diabetes patients are obvious to all, and scientific and rational drug use can prevent the occurrence and progress of DR, which can better benefit DR Patients.

Citation: Wu Cenyi, Li Xiaoxia, Shen Yu, Wu Miaoqin. Research progress in prevention and cure of glucagon-like peptide-1 receptor agonists-1 receptor agonists for diabetic retinopathy. Chinese Journal of Ocular Fundus Diseases, 2024, 40(2): 153-158. doi: 10.3760/cma.j.cn511434-20230424-00184 Copy

  • Previous Article

    急性渗出性多形性卵黄样黄斑病变1例
  • Next Article

    Research progress on the bidirectional effect of autophagy on retinal neurovascular unit cells in diabetic retinopathy